Recordati stock holds steady as 2026 guidance targets higher revenue and margins
Published on 08/26/2026 at 14:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Recordati S.p.A. (ISIN IT0003828271) stock is trading close to its recent level on August 26, 2026, while management has set clear financial targets for fiscal 2026 that point to higher net revenue and solid profitability margins.
2026 guidance frames the earnings outlook
Per a guidance update released on August 26, 2026, management expects fiscal 2026 net revenue between EUR 2,730 million and EUR 2,800 million, with the range reflecting anticipated foreign-exchange headwinds in the period. The guidance document indicates that this revenue range is set for the full fiscal year 2026 and incorporates a negative FX impact quantified as a 3.5 percent headwind compared with a neutral currency scenario.
The same release sets an EBITDA target between EUR 995 million and EUR 1,030 million for fiscal 2026, corresponding to a margin of about 36.5 percent on net revenue. In the guidance table, the margin indication is expressed as a band around 36.5 percent, which implies that management is planning for a profitability level that remains firmly in the mid-30s on an EBITDA basis even after incorporating the FX headwind.
Adjusted net income for fiscal 2026 is targeted in a range between EUR 655 million and EUR 685 million, corresponding to an adjusted net margin close to 24.0 percent. The same guidance overview specifies this margin band around 24.0 percent, underscoring that Recordati aims to sustain a quarter of its revenue as adjusted net profit at group level in 2026.
Revenue and earnings targets in context
The 2026 net revenue range of EUR 2,730 million to EUR 2,800 million implies an increase versus fiscal 2025 if one assumes that prior-year revenue was lower, and the explicit FX headwind of 3.5 percent suggests that underlying operational growth is stronger than the reported figures will show once currency translation effects are accounted for. Even with FX subtracting value from reported numbers, the midpoint of the revenue range, EUR 2,765 million, signals a sizeable top-line scale for Recordati in 2026.
On profitability, the EBITDA band of EUR 995 million to EUR 1,030 million illustrates that management expects the business to generate just over one third of revenue as EBITDA. Taking the midpoint of the EBITDA range, EUR 1,012.5 million, against the revenue midpoint, EUR 2,765 million, yields an implied EBITDA margin slightly above 36.5 percent, consistent with the margin guidance stated in the release. That relationship highlights the company’s focus on maintaining operating efficiency even under FX pressure.
The adjusted net income range of EUR 655 million to EUR 685 million similarly points to robust earnings power. Using the midpoint of EUR 670 million and dividing by the revenue midpoint of EUR 2,765 million gives an implied adjusted net margin in line with the guided 24.0 percent band. For investors, that margin level indicates that Recordati expects to convert almost one quarter of its sales into adjusted net profit in 2026, a level that supports dividend capacity and potential reinvestment in growth.
Market data and sector positioning
On the equity market side, recent quote data compiled on August 26, 2026, show Recordati shares trading at EUR 52.78 on a European venue, with the listing noted as part of a sector consensus overview. The quote snapshot states that at EUR 52.78 the stock has posted a five-day change of 0.00 percent, while the change since January 1 stands at 0.29 percent, suggesting that the shares have been relatively stable so far this year in price terms.
The same market overview lists another level at EUR 28.61 with a daily change of 2.27 percent, indicating that, within related instruments tied to Recordati, at least one line has seen intraday movement higher on the referenced date. The intraday data do not alter the broader picture of a stock that has only modestly appreciated year to date, but they show that individual trading sessions can still deliver noticeable percentage moves.
Combining the guidance ranges with the latest market snapshot, investors can compare the implied valuation metrics with sector peers. At a price level around EUR 52.78 and with a 2026 adjusted net income midpoint of EUR 670 million, the implied price-to-earnings multiple on adjusted 2026 earnings depends on the company’s share count, but the guidance alone suggests that Recordati plans to support its valuation with double-digit margins and clear revenue growth trajectories.
Representative product and business model
Recordati operates as a specialty pharmaceutical group headquartered in Milan, focusing on prescription drugs across cardiovascular, urology, and rare disease indications, among others. The company’s portfolio includes branded medicines for chronic conditions as well as orphan drugs, which are typically targeted at smaller patient populations but can command premium pricing and carry strong margin profiles. These product characteristics align with the financial guidance that emphasizes high margins and stable revenue streams.
A representative product from Recordati’s rare disease franchise is a treatment used for specific metabolic or genetic conditions, marketed in multiple European and international markets. In this segment, revenue visibility can often be supported by long therapy durations and reimbursement arrangements, which in turn underpin the ability to project EBITDA and net income margins with confidence over a multi-year horizon.
Stock view and closing data point
As of August 26, 2026, the most recent available market data show Recordati stock trading in the low-fifties in EUR terms on European exchanges, with the year-to-date change documented as 0.29 percent and the five-day performance flat. While the shares have not delivered strong price gains so far in 2026, the company’s guidance pointing to net revenue between EUR 2,730 million and EUR 2,800 million, EBITDA between EUR 995 million and EUR 1,030 million, and adjusted net income between EUR 655 million and EUR 685 million provides a quantitative framework that investors can use to reassess the balance between current valuation and expected earnings power.
Read more
More on Recordati stock and the company’s investor communication can be found in the latest guidance release for fiscal 2026, which details the revenue, EBITDA, and adjusted net income ranges and their associated margins.
Fact box
Company: Recordati S.p.A.
ISIN: IT0003828271
Ticker: not specified
Exchange: Italian main market (EUR listing)
Price (as of August 26, 2026): EUR 52.78
Market cap: not specified
Sector / Industry: Pharmaceuticals
Index membership: not specified
